
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Our continuation of a survey on the accuracy of a recent article “Talk Doesn’t Pay, So Psychiatry Turns Instead to Drug Therapy” that seems to reduce the practice of psychiatry to a 15-minute med check.
Psychiatric Times continues its survey on the accuracy of the recent New York Times article “






